Basel, SwitzerlandMay 2022
Engimmune Therapeutics raised €15M in a Seed round in May 2022. The company is based in Basel, Switzerland. Investors in the round: Novo Holdings, Pureos Bioventures. Data as of Nov 2026.
Amount raised
€15M
€15,089,564
Native amount
15,500,000 CHF
Stage
Seed
seed
Investors
2
Provenance & confidence
High confidenceAmount
15,500,000 CHF
ECB-at-date → €15M · rate 1.0272 on 2022-05-03
High confidence
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
Investors in this round
2 namedDate
May 2022
Round type
seed
Amount (EUR)
€15M
Other rounds
same companyRelated news
- BaseLaunch invests USD 1.5 million in three new startupsstartupticker.ch · 2022-02
- Engimmune Therapeutics raises CHF 15.5 million in seed financingstartupticker.ch · 2022-05